Viking Therapeutics, Inc. (Nasdaq: VKTX) is excited to announce the successful completion of a $100 million funding round aimed at propelling its innovative therapies for metabolic and endocrine disorders into the next phase of clinical trials. As a clinical-stage biopharmaceutical company, Viking is dedicated to developing first-in-class and best-in-class treatments, and this substantial influx of capital will significantly further our mission. The funds will primarily support our most advanced candidate, a non-steroidal selective androgen receptor modulator (SARM), currently undergoing Phase 2 trials for the treatment of recovery from hip fracture surgery. In addition, the funding will enhance our ongoing efforts with our thyroid receptor beta (TRb) agonist platform, which targets a range of lipid disorders such as hypercholesterolemia, as well as the management of fatty liver diseases including non-alcoholic steatohepatitis (NASH). Notably, our research also extends to the treatment of rare diseases such as glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy (X-ALD). With this significant investment, Viking is well-positioned to accelerate its pipeline and advance sustainable solutions for patients suffering from these often-overlooked conditions. We were fortunate to gain the support of investors who share our vision for transforming the landscape of metabolic health and improving patient outcomes across the globe. To stay updated on our progress, please visit us at http://www.vikingtherapeutics.com.
Viking Therapeutics Raises $100M for Groundbreaking Metabolic Disorder Therapies
Recently funded 路 $100.0MHealthcare
Get the full Viking Therapeutics, Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
